Start Date
January 31, 2025
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2029
Anti-Thymocyte Globulin (ATG)
2.5 mg/kg administered as two divided infusions of 0.5 mg/kg and 2 mg/kg on Days 1 and 2.
Interleukin 2
1 million IU per dose administered subcutaneously for 5 consecutive days on Days 10-14, and then every two weeks.
Exenatide
2 mg administered subcutaneously weekly for up to 52 weeks.
Adalimumab
50 mg administered subcutaneously once a month for 1 year.
ATG Placebo
ATG placebo mimicking Thymoglobulin administered intravenously.
IL-2 Placebo
IL-2 placebo mimicking Aldesleukin administered subcutaneously.
Adalimumab Placebo
Placebo mimicking Adalimumab administered subcutaneously.
Exenatide Placebo
Placebo mimicking Exenatide administered subcutaneously.
Diabetes Research Institute, University of Miami Miller School of Medicine, Miami
Collaborators (1)
Diabetes Research Institute Foundation
OTHER
Camillo Ricordi and Jay Skyler
OTHER